On September 30, WUXI BIO rose 3.27% in regular trading, trading at 55.3 HKD/share, with turnover of approximately 457 million HKD. The stock extended its recent upward momentum supported by a confluence of positive catalysts.

On the news front, multiple brokerages raised their target price for WUXI BIO to 60 HKD while maintaining Buy ratings. The recently released national pharmaceutical industry development plan explicitly supports the CDMO/CRO sector, while rising AI-driven drug discovery commercialization expectations and a strengthening innovative drug overseas expansion thesis continue to boost sentiment across the CXO space. Northbound capital recorded a net purchase of approximately 45.82 million HKD in WUXI BIO in the prior trading session, providing additional support on the capital flow side.

The rally also builds on strong interim results disclosed in late August. The company reported first-half revenue of 11.787 billion RMB, with gross margin improving from 42.7% to 46.2% year-over-year. Operating cash flow surged 137.2%, while XDC external sales grew 37.8%. Full-year revenue growth guidance was raised to 15%-18%. Additionally, the company completed the cancellation of 39.82 million previously repurchased shares in mid-September, further enhancing shareholder value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)